Please use this identifier to cite or link to this item:
Title: Translational medicine in hereditary hemorrhagic telangiectasia
Author: Riera Mestre, Antoni
Cerdà, Pau
Iriarte, Adriana
Graupera i Garcia-Milà, Mariona
Viñals Canals, Francesc
Keywords: Angiogènesi
Malalties rares
Malalties hereditàries
Rare diseases
Genetic diseases
Issue Date: 16-Sep-2021
Publisher: Elsevier B.V.
Abstract: Scientific community have gained lots of new insights in the genetic and biochemical background of different conditions, rare diseases included, settling the basis for preclinical models that are helping to identify new biomarkers and therapeutic targets. Translational Medicine (TM) is an interdisciplinary area of biomedicine with an essential role in bench-to-bedside transition enhancement, generating a circular flow of knowledge transference between research environment and clinical setting, always centered in patient needs. Here, we present different tools used in TM and an overview of what is being done related to hereditary hemorrhagic telangiectasia (HHT), as a disease's model. This work is focused on how this combination of basic and clinical research impacts in HHT patient's daily clinical management and also looking into the future. Further randomized clinical trials with HHT patients should assess the findings of this bench-to-bedside transition. The benefits of this basic and clinical research combination, may not only be important for HHT patients but for patients with other vascular diseases sharing angiogenic disturbances.
Note: Versió postprint del document publicat a:
It is part of: European Journal Of Internal Medicine, 2021, vol. 95, num. 2022, p. 32-37
Related resource:
ISSN: 0953-6205
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
720452.pdf810.31 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons